Apellis Pharmaceuticals To Present Phase 3 VALIANT Study Results On Pegcetacoplan At ASN Kidney Week

Apellis Pharmaceuticals, Inc. announced that the abstract for the Phase 3 VALIANT study of pegcetacoplan in C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) has been accepted for an oral presentation at the American Society of Nephrology (ASN) Kidney Week. The high Impact Clinical Trials will be featured in the prestigious oral presentation session. Additionally, two more abstracts on pegcetacoplan related to C3G and primary IC-MPGN will be presented as posters. Kidney Week will take place from October 23-27 in San Diego, CA.

The oral presentation details during high-impact clinical trial sessions are as follows: 

• VALIANT: Dr. Carla Nester, MD, MSA, FASN, will present a Phase 3 trial on pegcetacoplan—a randomized, double-blind, placebo-controlled study targeting patients with native or post-transplant recurrent C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). This high-impact clinical trial session will take place in Hall D at the Convention Center on Saturday, October 26, at 11:00 a.m. PT.

  
  

The webinar details are as follows: 

• Dr. Carla Nester, along with Dr. Jean E. Robillard, professor and director of pediatric nephrology at Stead Family Children’s Hospital, and Dr. Cedric Francois, CEO of Apellis, will discuss the results from the Phase 3 VALIANT Study. This webinar is set for Saturday, October 26, at 12:30 p.m. PT.

  
  

The additional poster presentation details are as follows:

• Dr. Anuja Java will present the 52-week findings on pegcetacoplan for treating post-transplant recurrent C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN) as part of the NOBLE study. This session, covering C3G, TMA, MGRS, amyloidosis, and other related conditions, will take place at the Exhibition Hall in the Convention Center on Saturday, October 26, at 10:00 a.m. PT.

  
  

• Dr. Carla Nester will discuss the long-term safety and efficacy of pegcetacoplan in patients with C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis during the Long-Term VALE Extension Study presentation. This session will cover topics including C3G, TMA, MGRS, and amyloidosis. Join her at the Exhibition Hall in the Convention Center on Saturday, October 26, at 10:00 a.m. PT.

  
  

• The live webinar audio will be available on the “Events and Presentations” page of the “Investors and Media” section of the company’s website.